Yet, despite the high efficiency of anti-Ly6G antibody in the initial phase, at later stages of tumor progression depletion was technically impossible, at least with our approach, most likely due to the vast neutrophil numbers in JUNB-deficient mice. This evidence concerns the gene JUNB and neoplasm.